세계의 비호지킨 림프종 치료 시장 : 치료 유형, 용도, 최종 사용자별 예측(2025-2030년)

The Non-Hodgkin Lymphoma Treatment Market was valued at USD 8.20 billion in 2023, expected to reach USD 8.84 billion in 2024, and is projected to grow at a CAGR of 7.91%, to USD 13.98 billion by 2030.

The scope of the Non-Hodgkin Lymphoma (NHL) treatment market encompasses the diagnosis, treatment, and management of various subtypes of NHL, focusing on pharmacologic interventions such as chemotherapy, immunotherapy, targeted therapy, and radiation therapy. It pertains to healthcare providers, pharmaceutical companies, researchers, and patients seeking effective, innovative treatments. The necessity for NHL treatment is underscored by its prevalence and the unmet need for long-term, effective treatment options. This market has diverse applications including hospitals, cancer research institutes, and specialty clinics, with growing demand fueled by advances in precision medicine and increased healthcare expenditure. The end-use scope covers patients across demographics and stages of NHL, from initial diagnosis to relapse or remission monitoring. Market insights reveal growth influenced by the increasing incidence of NHL, advances in biotechnology, and the approval of novel treatment options. Challenges such as high treatment costs, adverse treatment-related side effects, and the complexity of NHL subtypes create hurdles for consistent patient outcomes. Opportunities arise with the advent of CAR T-cell therapy and bispecific antibodies, presenting significant potential for improved efficacy and personalized care. Recommendations include investing in R&D for innovative therapies, leveraging partnerships for enhanced clinical trials, and focusing on developing cost-effective treatment regimens. Constraints include stringent regulatory environments and reimbursement issues that may affect market accessibility. The best areas for innovation and research lie in enhancing the efficacy of immunotherapies, integrating artificial intelligence for prognosis and treatment strategies, and exploring combination therapies that combine different treatment modalities to improve patient outcomes. The NHL treatment market is competitive and dynamic, with a robust focus on scientific advancements, offering substantial potential for businesses dedicated to improving the quality of life and survival rates for NHL patients.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Hodgkin Lymphoma Treatment Market

The Non-Hodgkin Lymphoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of non-Hodgkin lymphoma disease
  • The launch of promising drugs and drug approval for lymphomas
  • Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
• Market Restraints
  • High cost of the treatment and certain side effects
• Market Opportunities
  • Increase in research and development of therapeutic drugs against the disease
  • Rising investments from government and non-profit organizations
• Market Challenges
  • Stringent regulations for cancer treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Non-Hodgkin Lymphoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Hodgkin Lymphoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-Hodgkin Lymphoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Hodgkin Lymphoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-Hodgkin Lymphoma Treatment Market

A detailed market share analysis in the Non-Hodgkin Lymphoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Hodgkin Lymphoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Hodgkin Lymphoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Hodgkin Lymphoma Treatment Market

A strategic analysis of the Non-Hodgkin Lymphoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell Transplantation, and Targeted Therapy.
• Based on Application, market is studied across Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
• Based on End-User, market is studied across Cancer Centers, Home Care, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
    • 5.1.1.2. The launch of promising drugs and drug approval for lymphomas
    • 5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of the treatment and certain side effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
    • 5.1.3.2. Rising investments from government and non-profit organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations for cancer treatment options
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
  • 5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
  • 5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Radiation Therapy
• 6.5. Stem Cell Transplantation
• 6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Application

• 7.1. Introduction
• 7.2. Diffuse Large B-cell Lymphoma
• 7.3. Follicular Lymphoma
• 7.4. Mantle Cell Lymphoma

8. Non-Hodgkin Lymphoma Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Cancer Centers
• 8.3. Home Care
• 8.4. Hospitals

9. Americas Non-Hodgkin Lymphoma Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • 12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
  • 12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Aurobindo Pharma
• 3. Bayer AG
• 4. Cipla Inc.
• 5. Dr. Reddy's Laboratories Ltd.
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche Ltd.
• 8. Gilead Sciences, Inc.
• 9. GlaxoSmithKline PLC
• 10. Hetero Drugs Ltd.
• 11. Hikma Pharmaceuticals PLC
• 12. Intas Pharmaceuticals Ltd.
• 13. Janssen Global Services, LLC
• 14. Kyowa Kirin Co., Ltd.
• 15. Lupin Ltd.
• 16. Merck KGaA
• 17. Nordic Nanovector ASA by Thor Medical
• 18. Novartis AG
• 19. Pharmacyclics, LLC
• 20. Salvavidas Pharmaceutical Pvt. Ltd.
• 21. Sanofi S.A.
• 22. Takeda Pharmaceutical Company Limited
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Zydus Pharmaceuticals